Unity Biotechnology selects UBX1967 as lead ophthalmology candidate

Unity Biotechnology has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug application and executed the compound license agreement for the compound with Ascentage Pharma under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema. Unity plans to file an IND application for UBX1967 in 2H19.
https://thefly.com/landingPageNews.php?id=2843517